StockNews.com Initiates Coverage on Bio-Path (NASDAQ:BPTH)

Analysts at StockNews.com initiated coverage on shares of Bio-Path (NASDAQ:BPTH) in a note issued to investors on Sunday. The firm set a “sell” rating on the stock.

Bio-Path Trading Down 1.9 %

Bio-Path stock opened at $0.80 on Friday. Bio-Path has a 12-month low of $0.61 and a 12-month high of $12.37. The firm has a 50 day simple moving average of $0.96 and a 200-day simple moving average of $1.49.

Institutional Trading of Bio-Path

An institutional investor recently bought a new position in Bio-Path stock. Armistice Capital LLC acquired a new position in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned approximately 4.66% of Bio-Path as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 5.74% of the company’s stock.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.